Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Summary

This phase II trial studies how well pazopanib hydrochloride works in treating patients with uterine cancer that has come back or has not responded to treatment. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of uterine cancer by blocking blood flow to the tumor.

Timeline

Start

2011-01

Primary completion

2016-01

Completion

2016-01

Drugs

Indications